Literature DB >> 24645986

Identification of novel kinase inhibitors by targeting a kinase-related apoptotic protein-protein interaction network in HeLa cells.

Z Shi1, N An, B M Lu, N Zhou, S L Yang, B Zhang, C Y Li, Z J Wang, F Wang, C F Wu, J K Bao.   

Abstract

OBJECTIVES: Protein kinases orchestrate activation of signalling cascades in response to extra- and intracellular stimuli for regulation of cell proliferation. They are directly involved in a variety of diseases, particularly cancers. Systems biology approaches have become increasingly important in understanding regulatory frameworks in cancer, and thus may facilitate future anti-cancer discoveries. Moreover, it has been suggested and confirmed that high-throughput virtual screening provides a novel, effective way to reveal small molecule protein kinase inhibitors. Accordingly, we aimed to identify kinase targets and novel kinase inhibitors.
MATERIALS AND METHODS: A series of bioinformatics methods, such as network construction, molecular docking and microarray analyses were performed.
RESULTS: In this study, we computationally constructed the appropriate global human protein-protein interaction network with data from online databases, and then modified it into a kinase-related apoptotic protein-protein interaction network. Subsequently, we identified several kinases as potential drug targets according to their differential expression observed by microarray analyses. Then, we predicted relevant microRNAs, which could target the above-mentioned kinases. Ultimately, we virtually screened a number of small molecule natural products from Traditional Chinese Medicine (TCM)@Taiwan database and identified a number of compounds that are able to target polo-like kinase 1, cyclin-dependent kinase 1 and cyclin-dependent kinase 2 in HeLa cervical carcinoma cells.
CONCLUSIONS: Taken together, all these findings might hopefully facilitate discovery of new kinase inhibitors that could be promising candidates for anti-cancer drug development.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24645986      PMCID: PMC6496802          DOI: 10.1111/cpr.12098

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  48 in total

1.  Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening.

Authors:  Siyuan Li; Xianqiang Sun; Hongli Zhao; Yun Tang; Minbo Lan
Journal:  Bioorg Med Chem Lett       Date:  2012-04-27       Impact factor: 2.823

2.  DOCK 6: combining techniques to model RNA-small molecule complexes.

Authors:  P Therese Lang; Scott R Brozell; Sudipto Mukherjee; Eric F Pettersen; Elaine C Meng; Veena Thomas; Robert C Rizzo; David A Case; Thomas L James; Irwin D Kuntz
Journal:  RNA       Date:  2009-04-15       Impact factor: 4.942

Review 3.  A systems biology analysis of autophagy in cancer therapy.

Authors:  Zheng Shi; Chun-yang Li; Si Zhao; Yang Yu; Na An; Yong-xi Liu; Chuan-fang Wu; Bi-song Yue; Jin-ku Bao
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

4.  Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.

Authors:  David Olmos; Douglas Barker; Rohini Sharma; Andre T Brunetto; Timothy A Yap; Anne B Taegtmeyer; Jorge Barriuso; Hanine Medani; Yan Y Degenhardt; Alicia J Allred; Deborah A Smith; Sharon C Murray; Thomas A Lampkin; Mohammed M Dar; Richard Wilson; Johann S de Bono; Sarah P Blagden
Journal:  Clin Cancer Res       Date:  2011-04-01       Impact factor: 12.531

5.  Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells.

Authors:  Marcel A T M van Vugt; Alexandra Brás; René H Medema
Journal:  Mol Cell       Date:  2004-09-10       Impact factor: 17.970

6.  BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.

Authors:  Dorothea Rudolph; Martin Steegmaier; Matthias Hoffmann; Matthias Grauert; Anke Baum; Jens Quant; Christian Haslinger; Pilar Garin-Chesa; Günther R Adolf
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

7.  Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα.

Authors:  Hanna S Radomska; Meritxell Alberich-Jordà; Britta Will; David Gonzalez; Ruud Delwel; Daniel G Tenen
Journal:  J Clin Invest       Date:  2012-07-17       Impact factor: 14.808

8.  MINT: the Molecular INTeraction database.

Authors:  Andrew Chatr-aryamontri; Arnaud Ceol; Luisa Montecchi Palazzi; Giuliano Nardelli; Maria Victoria Schneider; Luisa Castagnoli; Gianni Cesareni
Journal:  Nucleic Acids Res       Date:  2006-11-29       Impact factor: 16.971

9.  Whole genome gene expression analysis reveals casiopeína-induced apoptosis pathways.

Authors:  Alejandra Idan Valencia-Cruz; Laura I Uribe-Figueroa; Rodrigo Galindo-Murillo; Karol Baca-López; Anllely G Gutiérrez; Adriana Vázquez-Aguirre; Lena Ruiz-Azuara; Enrique Hernández-Lemus; Carmen Mejía
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  The microRNA.org resource: targets and expression.

Authors:  Doron Betel; Manda Wilson; Aaron Gabow; Debora S Marks; Chris Sander
Journal:  Nucleic Acids Res       Date:  2007-12-23       Impact factor: 16.971

View more
  5 in total

1.  Identification of Novel Pathways in Plant Lectin-Induced Cancer Cell Apoptosis.

Authors:  Zheng Shi; Rong Sun; Tian Yu; Rong Liu; Li-Jia Cheng; Jin-Ku Bao; Liang Zou; Yong Tang
Journal:  Int J Mol Sci       Date:  2016-02-08       Impact factor: 5.923

2.  miR-328-3p mediates the anti-tumor effect in osteosarcoma via directly targeting MMP-16.

Authors:  Jianhui Shi; Gang An; Ying Guan; Tianli Wei; Zhibin Peng; Min Liang; Yansong Wang
Journal:  Cancer Cell Int       Date:  2019-04-23       Impact factor: 5.722

3.  Knockdown of miR-423-5p simultaneously upgrades the eNOS and VEGFa pathways in ADSCs and improves erectile function in diabetic rats.

Authors:  Jun Zhou; Yinghao Yin; Yuan Yang; Dongyi Peng; Jingchao Wei; Guangming Yin; Yuxin Tang
Journal:  J Cell Mol Med       Date:  2021-09-20       Impact factor: 5.310

4.  Glucocappasalin Induces G2/M-Phase Arrest, Apoptosis, and Autophagy Pathways by Targeting CDK1 and PLK1 in Cervical Carcinoma Cells.

Authors:  Guangya Xu; Xueling Yan; Zhongjia Hu; Lulu Zheng; Ke Ding; Yamei Zhang; Yi Qing; Tao Liu; Lijia Cheng; Zheng Shi
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

5.  Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening.

Authors:  Zheng Shi; Tian Yu; Rong Sun; Shan Wang; Xiao-Qian Chen; Li-Jia Cheng; Rong Liu
Journal:  Pharmacogn Mag       Date:  2016 Apr-Jun       Impact factor: 1.085

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.